Modality
Fusion Protein
MOA
Anti-Aβ
Target
AuroraA
Pathway
Tau
AS
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
Jan 2019
→ Jun 2026
Phase 1Current
NCT08430341
590 pts·AS
2019-01→2026-06·Recruiting
590 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-203mo awayInterim· AS
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1
Recruit…
Catalysts
Interim
2026-06-20 · 3mo away
AS
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08430341 | Phase 1 | AS | Recruiting | 590 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA | |
| RLA-6817 | Relay Therapeutics | Phase 3 | TIGIT |